By Anthony O. Goriainoff
NetScientific said that its portfolio company PDS Biotechnology announced data from the phase 2 clinical trial evaluating the safety and efficacy of cancer treatment PDS0101.
The trial data offered preliminary insights into how the treatment, combined with the Keytruda therapy, may affect specific molecules such as cytokines and chemokines in certain t-cells, the life-sciences and technology investment company said late Monday.
NetScientific said that the data, which was presented during the European Society for Medical Oncology Congress, also showed potential changes to the immune profile after treatment for head and neck cancer patients.
The company said the immune response data related to a preliminary analysis of a subset of patients in a phase 2 clinical trial evaluating the safety and efficacy of PDS0101 in combination with Keytruda in patients with human papillomavirus 16-positive recurrent or metastatic head and neck squamous cell carcinoma.
“Such studies could be helpful in providing further insight into how PDS0101 in combination with Keytruda alters T-cell cytokine and chemokine profiles to promote improved clinical outcomes,” the company said.
Write to Anthony O. Goriainoff at [email protected]
Read the full article here